- Stock price has shot up 150% to 200% since January 2017 to carry a 100 million
dollar market cap.
- Company has progressed three novel targeted anticancer
therapies in early stage
- Cash runway is stable through 2018, but more capital raises expected in 2017.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) is a clinical stage biotechnology
company dedicated to targeting specific proteins localized in human cancer cells but not in
healthy tissues for the treatment of cancer. This approach is in conjunction with this
current trend in cancer research to increase efficacy and safety. RNN has three major
drug candidates in clinical trials for some tough cancers with unmet or under met markets.
RNN is developing its first candidate, RX3117, in ongoing phase 2 clinical trials for treatment of metastatic pancreatic cancer and metastatic muscle invasive bladder cancer.
Supinoxin, its second candidate, is being evaluated in phase 2 clinical trial in patients with
metastatic triple negative breast cancer. Finally, Archexin is under analysis in a phase 2
clinical trial in patients with metastatic renal cell carcinoma.